Table 3.
Multivariable regression analysis for mortality and neurological outcome.
| Survivors, Tau Levels | Nonsurvivors, Tau Levels | OR (95%CI) | p | AUC |
OR (95%CI) Age + Gender |
p |
OR (95%CI) Comorbidities + Age + Gender |
p | OR (95%CI) Initial Status + Age + Gender | p |
OR (95%CI) Blood Markers + Age + Gender |
p |
OR (95%CI) Resuscitation Measures + Age + Gender |
p | |
| Tau levels, median (IQR) | 94.1 (71.5, 133) |
108.5 (74.3, 175) |
2.90 (0.99 to 8.53) |
0.05 | 0.57 | 3.93 (1.25 to 12.40) |
0.02 | 4.12 (1.22 to 13.91) |
0.02 | 5.61 (1.62 to 19.41) |
0.01 | 3.74 (0.96 to 14.49) |
0.06 | 4.03 (1.03 to 15.83) |
0.05 |
| Q1, n (%) | 35 (58.3) | 25 (41.7) | 1 (reference) |
1 (reference) |
1 (reference) |
1 (reference) |
1 (reference) |
1 (reference) |
|||||||
| Q2, n (%) | 37 (60.7) | 24 (39.3) | 0.91 (0.44 to 1.88) |
0.80 | 0.85 (0.40 to 1.84) |
0.68 | 0.80 (0.36 to 1.79) |
0.58 | 0.98 (0.43 to 2.21) |
0.96 | 1.00 (0.42 to 2.40) |
1.00 | 0.90 (0.36 to 2.25) |
0.82 | |
| Q3, n (%) | 34 (55.7) | 27 (44.3) | 1.18 (0.57 to 2.44) |
0.65 | 1.25 (0.58 to 2.67) |
0.57 | 1.11 (0.49 to 2.51) |
0.81 | 1.57 (0.69 to 3.56) |
0.28 | 1.25 (0.53 to 2.95) |
0.61 | 1.07 (0.43 to 2.69) |
0.89 | |
| Q4, n (%) | 26 (43.3) | 34 (56.7) | 1.83 (0.89 to 3.78) |
0.10 | 2.03 (0.94 to 4.37) |
0.07 | 2.01 (0.89 to 4.53) |
0.09 | 2.53 (1.11 to 5.75) |
0.03 | 1.97 (0.82 to 4.73) |
0.13 | 2.30 (0.89 to 5.94) |
0.09 | |
| Good CPC, Tau Levels | Poor CPC, Tau Levels | OR (95%CI) | p | AUC | OR (95%CI) Age + Gender | p | OR (95%CI) Comorbidities + Age + Gender | p | OR (95%CI) Initial Status + Age + Gender | p | OR (95%CI) Blood Markers + Age + Gender | p | OR (95%CI) Resuscitation Measures + Age + Gender | p | |
| Tau levels, median (IQR) | 90.3 (71.5, 130) |
106.5 (74.3, 171) |
2.69 (0.91 to 7.89) |
0.07 | 0.57 | 3.49 (1.11 to 10.92) |
0.03 | 3.71 (1.13 to 12.25) |
0.03 | 4.43 (1.28 to 15.25) |
0.02 | 3.49 (0.89 to 13.65) |
0.07 | 4.17 (0.97 to 17.90) |
0.06 |
| Q1, n (%) | 30 (50) | 30 (50) | 1 (reference) |
1 (reference) |
1 (reference) |
1 (reference) |
1 (reference) |
1 (reference) |
|||||||
| Q2, n (%) | 32 (52.5) | 29 (47.5) | 0.91 (0.44 to 1.85) |
0.79 | 0.87 (0.41 to 1.85) |
0.72 | 0.80 (0.36 to 1.76) |
0.58 | 1.02 (0.46 to 2.27) |
0.97 | 1.06 (0.45 to 2.49) |
0.89 | 0.88 (0.34 to 2.25) |
0.79 | |
| Q3, n (%) | 29 (47.5) | 32 (52.5) | 1.19 (0.58 to 2.43) |
0.64 | 1.24 (0.58 to 2.63) |
0.58 | 1.15 (0.51 to 2.59) |
0.74 | 1.48 (0.65 to 3.35) |
0.35 | 1.26 (0.54 to 2.94) |
0.59 | 1.04 (0.40 to 2.68) |
0.94 | |
| Q4, n (%) | 21 (35) | 39 (65) | 1.86 (0.89 to 3.87) |
0.10 | 2.01 (0.93 to 4.35) |
0.08 | 2.00 (0.88 to 4.53) |
0.10 | 2.36 (1.03 to 5.38) |
0.04 | 1.99 (0.83 to 4.80) |
0.13 | 2.64 (0.98 to 7.08) |
0.05 |
Data is presented as number (n) and percentage (%) or median (interquartile range) or odds ratio (OR) and 95% confidence interval (CI). Tau levels: taurine concentration in pg/mL; Q: quartile; p: p-value; AUC: area under the curve.